Mindray raises FY13 guidance in spite of “mixed bag” Q2
This article was originally published in Clinica
Executive Summary
Mindray Medical, one of China’s largest homegrown medtech companies, has put out what analysts deem to be a patchy performance in the second quarter this year. Nonetheless, this did not stop the firm from raising its outlook for full-year revenue growth, which it now expects to be 18%, up from its previous guidance of 17%.